Kevin Kunzmann

A discussion with a director from the American Public Health Association on what drives the increasing burden of mental illness in the US.

The IUD has been shown to provide 99% efficacy in pregnancy prevention in a 1700-patient trial.

A new assessment shows patients younger and older than 40 years both benefit in exacerbation rate and pre-bronchodilator FEV1.

A new study presented at CHEST 2019 shows pulmonologists and ILD specialists will either reduce or temporarily interrupt antifibrotic care, depending on the form of adverse events a patient is experiencing.

A new study shows that bronchoscopy practice, procedure, and tools vary by facility, and in assessment duration.

A study comparing the LAMA/LABA to monotherapy found patients without prior ICS treatment benefitted significantly, regardless of disease severity or symptoms.

A comparative cohort found inpatient and outpatient costs, both for respiratory and all-cause conditions, were less per month for patients on the antifibrotic.

New findings from the phase 3 trial show budesonide/ glycopyrrolate/ formoterol fumarate significantly reduces exacerbations among patients with no exacerbation history, compared to dual therapies.

A Cleveland Clinic study showed about 13% of its transfusions were in deference to current guidelines. That said, there's plenty of gray area for cause of care.

From medical marijuana to vape devices, there seems to be a divide in defining what's legal for use, and what's actually beneficial for users.

How the LAMA therapy manages one of the integral facets of COPD care.

While one disease is benefitting from advancing digital screening measures, the other has a standard therapy which could provide benefit to both.

A new study finds the months of January-March are most burdened with COPD exacerbation-based hospitalizations, mortality, and hospital costs.

How should physicians navigate the public belief that vaping is less harmful than cigarette smoking?

A new study shows the underutilized test could reveal an additional 9% of asthma diagnoses and potentially 8% of asthma-COPD overlap syndrome cases.

How the aclidinium bromide trial brings novel perspective to COPD care.

Asthma burden among women can vary based on their age. Are there varying methods of care?

Are diagnostics and drugs optimized for pulmonary hypertension?

Fewer than 2% of all patients hospitalized with pneumonia in 2014 received the vaccination.

The chronic respiratory disease is often under-diagnosed in female patients.

New ASCENT-COPD data show the therapy's benefit in reducing cardiovascular events among high-risk patients, along with significant exacerbation reduction.

The fixed-dose therapy was shown to reduce exacerbations, regardless of patient history, among those with increased cardiovascular risk.

What the introduction of aclidinium/formoterol could mean for patients with COPD.

The approved label update now indicates the therapy delays disease progression when used in combination with an approved oral background PAH therapy.

A new assessment from CHRONICLE study data show patient-reported assessment on disease control may be more accurate.

The drug class has become a mainstay in clinical practice and treatment plans. But could it reach greater, and wider, indications?

Investigators found similar rescue treatment use among patients who do and do not have frequent exacerbations.

A study observing the effect of formulary changes to children with asthma show FEV and FEF scores worsened significantly when switching inhaler types.

The most recent CDC data, presented at CHEST 2019, show nearly 1500 patients have reported an associated lung injury, and 33 have died.

The indication expands the therapy to include newly diagnosed and persistent adults ITP patients who have had an insufficient response to therapy.